isabelobrien, Author at European Medical Journal - Page 28 of 29

An entrepreneurial approach to R&D

Decline in R&D productivity levels is rapidly becoming one of the biggest challenges for the pharmaceutical industry, but what can it do?

Amgen’s Victoria Elegant on driving innovation through diversity and inclusion

Victoria Elegant, Vice President and Region Head of Medical, Amgen, shares insights on the importance of diversity in delivering innovation, pharma in the JAPAC region and what medical affairs teams across the globe can learn from China.

Lead us on, medical affairs

Perfectly positioned to bridge the gap between R&D and commercial, MA must seize their strategic position within the industry to guide the future of the function.

Innovate to elevate HCP engagement

The regulatory ecosystem of the pharmaceutical industry and people’s decreasing attention spans is proving a complex reality for marketers that has provided an imperative to innovate.

Adherence: a bespoke regime

What helps people to stick to their medication regimes, and how can pharma begin to recover their revenue as well as striving for better health outcomes?

Introducing Spencer, CEO of The European Medical Group

For our very first podcast episode, we interview Spencer Gore our CEO, to define EMG, EMJ & GOLD. Listen now!

Roundtable: a moment with the millennial doctors

A roundtable discussion with two millennial doctors to find out what they want from pharma, both in terms of digital content, rep interactions and more.

Leo Pharma’s Gitte Aabo on the power of patient centricity

Gitte Aabo, President and CEO, LEO Pharma A/S, speaks about LEO’s leading position in dermatology and life-changing moments which help foster the patient-centric environment and mindset that is embedded so deeply within the company.

Roundtable: the singular best move for medical affairs

How can medical affairs teams construct a game plan to make sure they are prepared for the changing landscape within big data?

Only the brave marketers will succeed

Amid the digital and data revolution, the rise of social media, and increasing consumer expectations, pharma marketers must up their game to beat competitors.